CN103611162B - 人凝血因子ⅷ冻干保护剂及其制备方法 - Google Patents
人凝血因子ⅷ冻干保护剂及其制备方法 Download PDFInfo
- Publication number
- CN103611162B CN103611162B CN201310674256.6A CN201310674256A CN103611162B CN 103611162 B CN103611162 B CN 103611162B CN 201310674256 A CN201310674256 A CN 201310674256A CN 103611162 B CN103611162 B CN 103611162B
- Authority
- CN
- China
- Prior art keywords
- blood coagulation
- coagulation factors
- human blood
- factors viii
- freeze drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010039209 Blood Coagulation Factors Proteins 0.000 title claims abstract description 67
- 102000015081 Blood Coagulation Factors Human genes 0.000 title claims abstract description 67
- 239000003114 blood coagulation factor Substances 0.000 title claims abstract description 67
- 229940019700 blood coagulation factors Drugs 0.000 title claims abstract description 67
- 238000004108 freeze drying Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000009849 deactivation Effects 0.000 claims abstract description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 15
- 239000004471 Glycine Substances 0.000 claims abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 9
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 9
- 239000001110 calcium chloride Substances 0.000 claims abstract description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 9
- 229960005337 lysine hydrochloride Drugs 0.000 claims abstract description 9
- 239000001509 sodium citrate Substances 0.000 claims abstract description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 9
- 239000011265 semifinished product Substances 0.000 claims description 11
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000011550 stock solution Substances 0.000 claims description 7
- 102000057593 human F8 Human genes 0.000 claims description 5
- 229960000900 human factor viii Drugs 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000008227 sterile water for injection Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 21
- 102000008100 Human Serum Albumin Human genes 0.000 abstract description 17
- 108091006905 Human Serum Albumin Proteins 0.000 abstract description 17
- 230000002779 inactivation Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 238000010438 heat treatment Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000003223 protective agent Substances 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000002633 protecting effect Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000003204 osmotic effect Effects 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 13
- 230000009477 glass transition Effects 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102100026735 Coagulation factor VIII Human genes 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 241001044369 Amphion Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000003686 blood clotting factor concentrate Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- -1 saccharide alcohols Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本公司产品 | |
冻干后外观 | 乳白色疏松体 |
溶解时间(分钟) | <1分钟 |
水分 | 合格 |
真空度 | 合格 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310674256.6A CN103611162B (zh) | 2013-12-11 | 2013-12-11 | 人凝血因子ⅷ冻干保护剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310674256.6A CN103611162B (zh) | 2013-12-11 | 2013-12-11 | 人凝血因子ⅷ冻干保护剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103611162A CN103611162A (zh) | 2014-03-05 |
CN103611162B true CN103611162B (zh) | 2015-09-16 |
Family
ID=50161894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310674256.6A Active CN103611162B (zh) | 2013-12-11 | 2013-12-11 | 人凝血因子ⅷ冻干保护剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103611162B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105879038A (zh) * | 2016-05-27 | 2016-08-24 | 成都蓉生药业有限责任公司 | 一种制备人凝血酶原复合物的干热处理稳定剂及其用途 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106139127B (zh) * | 2016-08-05 | 2020-04-07 | 无锡药明生物技术股份有限公司 | 重组凝血因子ⅷ冻干制剂 |
CN107337727A (zh) * | 2017-08-03 | 2017-11-10 | 国药集团武汉血液制品有限公司 | 一种血源性人凝血因子ⅷ制备方法 |
CN115429762B (zh) * | 2022-10-13 | 2023-07-14 | 国药集团武汉血液制品有限公司 | 用于高浓度纤维蛋白溶酶原制剂的冻干保护剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102430116A (zh) * | 2011-08-19 | 2012-05-02 | 上海新兴医药股份有限公司 | 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂 |
CN102580062A (zh) * | 2012-03-09 | 2012-07-18 | 中国医学科学院输血研究所 | 人凝血因子Ⅷ与vWF复合物或人凝血因子Ⅷ制剂的干热处理稳定剂 |
-
2013
- 2013-12-11 CN CN201310674256.6A patent/CN103611162B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102430116A (zh) * | 2011-08-19 | 2012-05-02 | 上海新兴医药股份有限公司 | 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂 |
CN102580062A (zh) * | 2012-03-09 | 2012-07-18 | 中国医学科学院输血研究所 | 人凝血因子Ⅷ与vWF复合物或人凝血因子Ⅷ制剂的干热处理稳定剂 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105879038A (zh) * | 2016-05-27 | 2016-08-24 | 成都蓉生药业有限责任公司 | 一种制备人凝血酶原复合物的干热处理稳定剂及其用途 |
CN105879038B (zh) * | 2016-05-27 | 2020-03-27 | 成都蓉生药业有限责任公司 | 一种制备人凝血酶原复合物的干热处理稳定剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103611162A (zh) | 2014-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI285112B (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
ES2275992T5 (es) | Composiciones farmacéuticas de toxina botulínica. | |
US10610600B2 (en) | Stabilizing excipients for therapeutic protein formulations | |
CA2680193C (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
CN103611162B (zh) | 人凝血因子ⅷ冻干保护剂及其制备方法 | |
CN104231073B (zh) | 一种人凝血因子viii的制备方法 | |
JP2012051895A (ja) | ウイルス不活性化熱処理へ供するための血漿タンパク質の寒冷沈降物を安定化する方法 | |
CN104225601B (zh) | 人凝血因子viii冻干及干热处理保护剂 | |
CN100542611C (zh) | 含有重组人血清白蛋白-干扰素α融合蛋白的注射用水剂 | |
CN109395074A (zh) | 一种乙型脑炎灭活疫苗冻干制剂及其制备方法 | |
US20100297081A1 (en) | Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein | |
CN106668867A (zh) | 一种不含明胶和人血白蛋白的腮腺炎疫苗冻干保护剂 | |
CN102430116A (zh) | 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂 | |
NZ235153A (en) | Stabilised alpha-interferon compositions | |
CN104888196A (zh) | 一种稳定的干扰素α多剂量笔注射液 | |
CN100577149C (zh) | 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方 | |
KR930008908B1 (ko) | 조직형 플라스미노겐 활성화제 또는 그의 유도체를 함유하는 혈전용해 조성물 | |
CN108492860B (zh) | 一种基于3d扫描技术的同种异体富含血小板血浆除皱美容复合物的药物定量方法 | |
CN106456695A (zh) | Hgf的冻干配制品 | |
JPH05501417A (ja) | 低温殺菌中の血漿安定化のための配合物 | |
CN102228676B (zh) | 一种肝水解肽注射液药物组合物 | |
JP2009062384A (ja) | ヒト血液凝固第xiii因子の安定化された水性液製剤 | |
CN103432573A (zh) | 重组人血清白蛋白-干扰素α融合蛋白的水溶液及其制备方法 | |
JPH03148226A (ja) | 動物臓器由来蛋白質のウィルス不活化法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171024 Address after: 430207, No. 1, No. 1, Golden Industrial Road, Zhengzhou City, Jiangxia District, Hubei, Wuhan Patentee after: SINOPHARM WUHAN BLOOD PRODUCT CO.,LTD. Address before: 430060, Linjiang Avenue, Wuchang District, Hubei, Wuhan, 9 Patentee before: WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 430207 No.1-1, Huangjin Industrial Park Road, Zhengdian, Jiangxia District, Wuhan City, Hubei Province Patentee after: Wuhan Biopharmaceutical Co., Ltd. of China National Pharmaceutical Group Address before: 430207 No.1-1, Huangjin Industrial Park Road, Zhengdian, Jiangxia District, Wuhan City, Hubei Province Patentee before: SINOPHARM WUHAN BLOOD PRODUCT CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |